Synthetic Vaccine Particles (SVP™) are targeted to interact with immune cells and induce antigen-specific immune responses. SVP are compatible with a wide range of antigens and immunomodulators. The broad applicability and manufacturing scalability that we have demonstrated with our SVP technology platform continues to enable us to engage in collaborations with leading industry organizations.
For further information about Selecta and the company’s collaboration opportunities, please contact email@example.com.
Together with Sanofi, Selecta Biosciences and The Juvenile Diabetes Research Foundation (JDRF) are collaborating to research SVP formulations for the treatment of type 1 diabetes, an autoimmune disorder. In September 2014, JDRF and Sanofi awarded a grant to Selecta Biosciences in furtherance of this program.
Genethon is providing adeno-associated virus (AAV)-based gene therapies and animal models to enable the use of SVP products to mitigate the formation of anti-drug antibodies and to enable repeat administration in gene therapy.
In 2014, Selecta Biosciences was awarded an $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH), to support research into the development of a next-generation vaccine for smoking cessation and relapse prevention.
In 2013, Selecta Biosciences was awarded a $1.2 million grant from the Bill and Melinda Gates Foundation to fund the Company’s immune stimulation program for a prophylactic malaria vaccine. This grant work has been expanded to $1.6 million in total.
The Skolkovo Foundation has committed up to $2.7 million in research funding to support Selecta’s development of an immunostimulatory therapeutic SVP to treat human papilloma virus-associated cancers by stimulating the immune system.